211 related articles for article (PubMed ID: 36721240)
1. Identification of cerebral spinal fluid protein biomarkers in Niemann-Pick disease, type C1.
Campbell K; Cawley NX; Luke R; Scott KEJ; Johnson N; Farhat NY; Alexander D; Wassif CA; Li W; Cologna SM; Berry-Kravis E; Do AD; Dale RK; Porter FD
Biomark Res; 2023 Jan; 11(1):14. PubMed ID: 36721240
[TBL] [Abstract][Full Text] [Related]
2. Elevated cerebrospinal fluid ubiquitin C-terminal hydrolase-L1 levels correlate with phenotypic severity and therapeutic response in Niemann-Pick disease, type C1.
Cawley NX; Giddens S; Farhat NM; Luke RA; Scott KEJ; Mohamed HO; Dang Do A; Berry-Kravis E; Cologna SM; Liu F; Porter FD
Mol Genet Metab; 2023 Nov; 140(3):107656. PubMed ID: 37517328
[TBL] [Abstract][Full Text] [Related]
3. Neurofilament light chain in cerebrospinal fluid as a novel biomarker in evaluating both clinical severity and therapeutic response in Niemann-Pick disease type C1.
Agrawal N; Farhat NY; Sinaii N; Do AD; Xiao C; Berry-Kravis E; Bianconi S; Masvekar R; Bielekova B; Solomon B; Porter FD
Genet Med; 2023 Mar; 25(3):100349. PubMed ID: 36470574
[TBL] [Abstract][Full Text] [Related]
4. Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial.
Ory DS; Ottinger EA; Farhat NY; King KA; Jiang X; Weissfeld L; Berry-Kravis E; Davidson CD; Bianconi S; Keener LA; Rao R; Soldatos A; Sidhu R; Walters KA; Xu X; Thurm A; Solomon B; Pavan WJ; Machielse BN; Kao M; Silber SA; McKew JC; Brewer CC; Vite CH; Walkley SU; Austin CP; Porter FD
Lancet; 2017 Oct; 390(10104):1758-1768. PubMed ID: 28803710
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic expression of swallowing function in Niemann-Pick disease type C1.
Solomon BI; Muñoz AM; Sinaii N; Farhat NM; Smith AC; Bianconi S; Dang Do A; Backman MC; Machielse L; Porter FD
Orphanet J Rare Dis; 2022 Sep; 17(1):342. PubMed ID: 36064725
[TBL] [Abstract][Full Text] [Related]
6. Long-term administration of intravenous Trappsol® Cyclo™ (HP-β-CD) results in clinical benefits and stabilization or slowing of disease progression in patients with Niemann-Pick disease type C1: Results of an international 48-week Phase I/II trial.
Sharma R; Hastings C; Staretz-Chacham O; Raiman J; Paucar M; Spiegel R; Murray B; Hurst B; Liu B; Kjems L; Hrynkow S
Mol Genet Metab Rep; 2023 Sep; 36():100988. PubMed ID: 37670901
[TBL] [Abstract][Full Text] [Related]
7. Swallowing characterization of adult-onset Niemann-Pick, type C1 patients.
Solomon BI; Muñoz AM; Sinaii N; Mohamed H; Farhat NM; Alexander D; Do AD; Porter FD
Orphanet J Rare Dis; 2024 Jun; 19(1):231. PubMed ID: 38863022
[TBL] [Abstract][Full Text] [Related]
8. Human and mouse neuroinflammation markers in Niemann-Pick disease, type C1.
Cologna SM; Cluzeau CV; Yanjanin NM; Blank PS; Dail MK; Siebel S; Toth CL; Wassif CA; Lieberman AP; Porter FD
J Inherit Metab Dis; 2014 Jan; 37(1):83-92. PubMed ID: 23653225
[TBL] [Abstract][Full Text] [Related]
9. Intravenous 2-hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™) demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and peripheral tissues in adult subjects with Niemann-Pick Disease Type C1: Results of a phase 1 trial.
Hastings C; Liu B; Hurst B; Cox GF; Hrynkow S
Mol Genet Metab; 2022 Dec; 137(4):309-319. PubMed ID: 36279795
[TBL] [Abstract][Full Text] [Related]
10. Reduction of glutamate neurotoxicity: A novel therapeutic approach for Niemann-Pick disease, type C1.
Cougnoux A; Yerger JC; Fellmeth M; Serra-Vinardell J; Navid F; Wassif CA; Cawley NX; Porter FD
Mol Genet Metab; 2021 Dec; 134(4):330-336. PubMed ID: 34802899
[TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein E genotype and neurological disease onset in Niemann-Pick disease, type C1.
Fu R; Yanjanin NM; Elrick MJ; Ware C; Lieberman AP; Porter FD
Am J Med Genet A; 2012 Nov; 158A(11):2775-80. PubMed ID: 23023945
[TBL] [Abstract][Full Text] [Related]
12. A differential proteomics study of cerebrospinal fluid from individuals with Niemann-Pick disease, Type C1.
Li W; Pergande MR; Crutchfield CA; Searle BC; Backlund PS; Picache JA; Burkert K; Yanjanin-Farhat NM; Blank PS; Toth CL; Wassif CA; Porter FD; Cologna SM
Proteomics; 2023 Jun; 23(11):e2200378. PubMed ID: 36638187
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal Fluid Calbindin D Concentration as a Biomarker of Cerebellar Disease Progression in Niemann-Pick Type C1 Disease.
Bradbury A; Bagel J; Sampson M; Farhat N; Ding W; Swain G; Prociuk M; O'Donnell P; Drobatz K; Gurda B; Wassif C; Remaley A; Porter F; Vite C
J Pharmacol Exp Ther; 2016 Aug; 358(2):254-61. PubMed ID: 27307499
[TBL] [Abstract][Full Text] [Related]
14. Niemann-Pick C variant detection by altered sphingolipid trafficking and correlation with mutations within a specific domain of NPC1.
Sun X; Marks DL; Park WD; Wheatley CL; Puri V; O'Brien JF; Kraft DL; Lundquist PA; Patterson MC; Pagano RE; Snow K
Am J Hum Genet; 2001 Jun; 68(6):1361-72. PubMed ID: 11349231
[TBL] [Abstract][Full Text] [Related]
15. Assessment of plasma chitotriosidase activity, CCL18/PARC concentration and NP-C suspicion index in the diagnosis of Niemann-Pick disease type C: a prospective observational study.
De Castro-Orós I; Irún P; Cebolla JJ; Rodriguez-Sureda V; Mallén M; Pueyo MJ; Mozas P; Dominguez C; Pocoví M;
J Transl Med; 2017 Feb; 15(1):43. PubMed ID: 28222799
[TBL] [Abstract][Full Text] [Related]
16. Retinal axonal degeneration in Niemann-Pick type C disease.
Havla J; Moser M; Sztatecsny C; Lotz-Havla AS; Maier EM; Hizli B; Schinner R; Kümpfel T; Strupp M; Bremova-Ertl T; Schneider SA
J Neurol; 2020 Jul; 267(7):2070-2082. PubMed ID: 32222928
[TBL] [Abstract][Full Text] [Related]
17. Modeling Niemann-Pick disease type C1 in zebrafish: a robust platform for
Tseng WC; Loeb HE; Pei W; Tsai-Morris CH; Xu L; Cluzeau CV; Wassif CA; Feldman B; Burgess SM; Pavan WJ; Porter FD
Dis Model Mech; 2018 Aug; 11(9):. PubMed ID: 30135069
[TBL] [Abstract][Full Text] [Related]
18. A human iPSC-derived inducible neuronal model of Niemann-Pick disease, type C1.
Prabhu AV; Kang I; De Pace R; Wassif CA; Fujiwara H; Kell P; Jiang X; Ory DS; Bonifacino JS; Ward ME; Porter FD
BMC Biol; 2021 Oct; 19(1):218. PubMed ID: 34592985
[TBL] [Abstract][Full Text] [Related]
19. Necroptosis inhibition as a therapy for Niemann-Pick disease, type C1: Inhibition of RIP kinases and combination therapy with 2-hydroxypropyl-β-cyclodextrin.
Cougnoux A; Clifford S; Salman A; Ng SL; Bertin J; Porter FD
Mol Genet Metab; 2018 Dec; 125(4):345-350. PubMed ID: 30392741
[TBL] [Abstract][Full Text] [Related]
20. Identification of Niemann-Pick C1 disease biomarkers through sphingolipid profiling.
Fan M; Sidhu R; Fujiwara H; Tortelli B; Zhang J; Davidson C; Walkley SU; Bagel JH; Vite C; Yanjanin NM; Porter FD; Schaffer JE; Ory DS
J Lipid Res; 2013 Oct; 54(10):2800-14. PubMed ID: 23881911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
